News

The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.

The RELAX-AHF-2 trial demonstrated that serelaxin did not achieve its primary endpoints of reduction in cardiovascular death through day 180 or reduced declining heart failure through day five when

As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI)

Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against

Xadago has been approved as add-on therapy to levodopa/carbidopa to treat PD, which affects up to 10 million patients across the globe. Developed in the late 1960s, Levodopa

Lilly stated that abemaciclib in combination with fulvestrant was demonstrated to be superior to fulvestrant plus placebo, with the former showing statistically significant improvement in PFS in comparison. The

NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that

Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion of a US$90,000 convertible

In May 2014, both firms signed a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s Probody platform. The